This article is more than 5 years old. Information may no longer be current.
Spectral domain OCT provides a more complete picture of macular telangiectasia
Click Here to Manage Email Alerts
PARIS — Spectral domain optical coherence tomography has been a step forward in the study of macular telangiectasia, adding new information on the morphology and progression of this rare condition.
On OCT, a central cyst is visible, with underlying discontinuation by smaller cavitations of the photoreceptor layer.
Spectral domain OCT also provides additional evidence of how current treatments produce no modification of the lesion, although they might reduce the secondary subretinal neovascularization typical of the more advanced stages of the disease.
In consideration of this evidence, Gisele Soubrane, MD, said that there is no reason that justifies the use of anti-VEGF agents as a therapy for telangiectasia.
"I suspect that it is more of a fashionable than a rational therapy," she said at the meeting of the French Society of Ophthalmology. A few studies with bevacizumab showed anecdotal slight improvement of visual acuity, but no modification of the retinal thickness or reduction of the lesion.
Triamcinolone also showed some efficacy in improving visual acuity during the treatment, but at the price of severe complications, such as cataract, occurring as early as after the second injection.